Dropdown

EE - Estonia
All companies
    All persons

      Search word:

      Field/EMTAK

      CAMBREX TALLINN OÜ

      Media page and news feed
      ?
      ?
      profile visits
      11,028
      ?
      company tracker
      44
      This company's branding has already reached 11,028 peopleand his is followed by 44 Storybook users.On average, the company has been rated 4.8 points.but there i

      CAMBREX TALLINN OÜ current status

      2184939_andmerobot_99391772_a_xl.jpg
      Andmerobot
      Did you notice typos in the article?

      Dropdown

      This company's branding has already reached 11,028 peopleand his is followed by 44 Storybook users.On average, the company has been rated 4.8 points.but there is no comment.

      Tegevusaruanne 2025

      1991. aastal aktsiaseltsina loodud teadus- ja arendustegevuse ettevõte tegutseb orgaanilise sünteesikeemia ja keemilise analüüsi valdkondades. 2008. aastal liitus ettevõte USA börsil noteeritud kontserniga Cambrex (NYSE:CBM), mis oli 4. detsembril 2019. soetatud rahvusvahelise investeerimise firma Permira poolt. 2023.

      aastal sai Cambrex Tallinn ravimite toimeainete tootmisloa kliiniliste uuringute varajasteks faasideks. 2025.

      majandusaastal pakkus ettevõte orgaanilise sünteesi, väikemahulise tootmise ja keemilise analüüsi teenust kontserni teistele ettevõtetele kui ka farmaatsia sektorist klientidele. Aruandeaasta investeeringute eesmärgiks summas 159 369 (2024: 100 828 eurot) tuhat eurot oli eelkõige laiendada analüütiliste- ja sünteesi laborite seadmeparki. 2025. majandusaastal arendusväljaminekuid ei tehtud. Planeeritud investeeringud 2026. aastaks on 200 tuhat eurot. Ettevõtte tegevus on aastaringne. Ettevõttet juhib üheliikmeline juhatus, kelle üle teostab järelevalvet neljaliikmeline nõukogu. Arveldused klientide ja tarnijatega toimuvad põhiliselt eurodes, mille tõttu on võimalikud olulised valuutariskid maandatud. Ettevõttel puuduvad laenu- ja kapitalirenditehingud, mistõttu intressimäärade muutumisega seonduvad riskid puuduvad. Ettevõtel oli 2025. aastal keskmiselt 42 töötajat (2024: 46 inimest). Peamine keskkonna mõju avaldub eelkõige CO2 emissioonina energia kasutamisega aga ka emissioonina materjalide sisseostul.

      Käive 2025. aastal oli ettevõtte müügitulu 3 380 902 eurot (2024: 3 713 273 eurot).

      Plaanid järgmiseks aastaks

      Plaanid järgmiseks aastaks kontserni Cambrex ettevõttena jätkab osaühing 2026. aastal arendus- ja uurimustööde teostamist orgaanilise sünteesikeemia ja keemilise analüüsi valdkondades ning väikemahulise projektipõhise kliiniliste uuringute varajasteks faasideks ravimite toorainete, vahetoodete ja toimeainete tootmisega. Ettevõte näeb oma põhiliste klientidena ja koostööpartneritena kontserni teisi ning nende kliente. Lähiaastate investeeringutega täiustatakse eelkõige keemilise analüüsi seadmete rida ning ka tootmise varustust. Arendusväljaminekuid järgmiseks majandusaastaks planeeritud ei ole. Juhtkonna tänase parima teamise kohaselt Vene-Ukraina sõjal ega Iraani konfliktil olulist negatiivset mõju etteõtte tegevusele lähiajal ei ole.

      Peamised finantssuhtarvud: 2025 2024

      Müügitulu (eurodes) 3 380 902 3 713 273

      Tulukasv -8,95% 3,52%

      Puhaskasum/kahjum (eurodes) 102 158 359 068

      Puhasrentaablus 3,02% 9,67%

      Lühiajaliste kohustuste 4,13 3,63 kattekordaja

      ROA 3,90% 14,93%

      ROE 4,52% 16,64%

      Suhtarvude arvutamisel kasutatud valemid: (cid:127) Tulu kasv (%) = (müügitulu 2025– müügitulu 2024)/ müügitulu 2024 * 100 (cid:127) Puhasrentaablus (%) = puhaskasum/ müügitulu * 100 (cid:127) Lühiajaliste kohustuste kattekordaja (kordades) = käibevara/lühiajalised kohustused (cid:127) ROA (%) = puhaskasum/ varad kokku * 100 (cid:127) ROE (%) = puhaskasum/ omakapital kokku * 100

      Comments (0)

      Are you sure you want to delete this article?

      Dropdown

      all articles
      10396298_CAMBREX-TALLINN-OU_24210908_a_xl.jpeg
      CAMBREX TALLINN OÜ / Andmerobot

      Scalifying the development and production of the active substance on a reliable route to the market

      The development of the active substance is a critical step in the life cycle of any pharmaceutical, chemical or biotechnology project. If the aim is to lead t
      ssb.ee
      The development of the active substance is a critical step in the life cycle of any pharmaceutical, chemical or biotechnology project. If the aim is to lead the idea from laboratory to stable and controlled large-scale production, a partner is needed that can support the whole process - from the initial development stages to the production and scaling of the end materials. < Professional development of the active substance helps to ensure that each next stage is based on a solid technical basis. This means better process control, greater recovery, a clearer quality framework and a
      10396298_CAMBREX-TALLINN-OU_24210908_a_xl.jpeg
      CAMBREX TALLINN OÜ / Andmerobot

      Analysis services supporting development with quality, accuracy and flexibility

      If a specific data-based support is required in the development process, analysis services play a central role. Adjusted analytical testing and well-conside
      ssb.ee
      If a specific data-based support is required in the development process, analysis services play a central role. Adjusted analytical testing and well-considered methodological development help to ensure that each decision is based on reliable measurement, clear quality and practical applicability. This approach provides a solid basis for both early testing and further validation and optimisation. The services are designed for organisations that need flexible and accurate support at different stages of development. Whether the aim is to evaluate a new solution, improve the existing
      10396298_CAMBREX-TALLINN-OU_24210908_a_xl.jpeg
      CAMBREX TALLINN OÜ / Andmerobot

      Peptide solutions for the development of peptides and oligonucleotides

      Pepticide solutions provide reliable pathways for the development, production and further scaling of complex biomolecules. If the aim is to create quality pep
      ssb.ee
      Pepticide solutions provide reliable pathways for the development, production and further scaling of complex biomolecules. If the aim is to create quality peptide or oligonucleotide , it is important to select a partner who understands both the accuracy of the molecules and the flexibility of production. It is here that solutions that combine scientific precision, process control and development capacity create value. The services are suitable for research and development teams, biotechnology companies and laboratories that need specialised molecules for new applications, tests or product
      10396298_CAMBREX-TALLINN-OU_24210908_a_xl.jpeg
      CAMBREX TALLINN OÜ / Andmerobot

      Pharmaceutical services from development to production: reliable support for active substances, peptides and pharmaceutical forms

      Farma services covering the entire development route provide a clear advantage to pharmaceutical projects from the first stages. If the aim is to lead the activ
      ssb.ee
      Farma services covering the entire development route provide a clear advantage to pharmaceutical projects from the first stages. If the aim is to lead the active substance, pharmaceutical form or special development to the next milestone, a partner is needed that combines scientific precision, flexibility and quality-centred action. Cambrex provides development, production and analysis services for pharmaceutical programmes from early development to moving towards commercial acetate. This means that the whole process runs as a whole - from the production of active substance and format

      File a complaint

      Choose the comment attribute that you think it contains:

      False information
      Spam
      Hate speech
      Terrorism
      Other

      You want to report an inappropriate comment.

      Are you sure?

      Are you sure you want to delete this article?

      Loader

      Loader

      App Ad

      Scorestorybook Chrome extension

      The Storybook extension tells you which company's website you are currently on and how reliable that company is today. download extension

      See the background of the caller! Storybook App brings you direct contacts for 400,000 Estonian companies and individuals (managers, officials). The data is enriched with solvency and financial information.

      We value your privacy

      We use cookies to improve your browsing experience, provide personalized ads or content, and analyze our traffic. By clicking "allow all", you agree to our use of all cookies.